About Us

Technologies That Heal 

New Amsterdam Sciences (NAS) is a clinical-stage bioscience company focused on the research, development and licensing of small molecule antioxidant SOD mimetics and peptide analogues of Substance P. The company’s lead compound, NAS150, is being pursued for indications with the underlying conditions driven by oxidative stress (ROS) mediated inflammation. The company’s current focus is its’ phase 2 candidate for COVID-19. Other indications the company is pursuing are Multiple Sclerosis, Rheumatoid Arthritis, Pneumonia, Influenza as well as Progressive Supranuclear Palsy, Idiopathic Pulmonary Fibrosis, and Radiation-Induced Lung Injury. New Amsterdam Sciences is devoted to developing products with not only commercial value but having governmental appeal, with a focus on mass casualty biodefense applications.

Leadership

Michael K. Wilhelm, Chief Executive Officer, Co-Founder 
Extensive experience leading early-stage companies. Previously co-founded ImmuneRegen BioSciences, Inc. Has served as Managing Director of Foresight Capital Corporation. Contact Michael

Chris van de Wetering, Ph.D. – Executive Vice President
Brings extensive scientific and strategic expertise in public health and biodefense preparedness including medical countermeasures. He has served in a variety of roles including Research & Development, Policy, Program Management, and Strategic Planning for Federal clients including DoD, HHS, and DHS. His experience serves NAS especially well in the areas of strategic planning, drug development, partnerships, and leadership.

Jerry E. Toepfer, Vice President, Co-Founder
Owner and President of Imageworx, a partner of Labelworx, and a partner of Greenmarket Purveying Company. Specializing in cosmetic, medical, and pharmaceutical packaging, and experienced in sales management, business development, and growth management in a manufacturing setting
Hal N. Siegel, Ph.D., Chief Scientific Officer
Brings extensive scientific and regulatory affairs expertise. Previous positions include Chief Scientific Officer and Vice President at ImmuneRegen BioSciences, Vice President of Regulatory and Scientific Affairs at Zila, Inc., and serving as a consultant to multiple life science and IT companies. Contact Hal
Rick Leimbach, CFO Corporate Advisor, Carrollton Partners 
Mr. Leimbach has extensive experience in both the public and private sectors. He currently serves as Principal and Chief Financial Officer Advisor at Carrollton Partners. He now advises public and private companies with their financial reporting, corporate governance needs and helps to position them to raise capital and achieve the next level of success.

Board of Directors

Michael K. Wilhelm, Chairman, Co-Founder 
Extensive experience leading early-stage companies. Previously co-founded ImmuneRegen BioSciences, Inc. Has served as Managing Director of Foresight Capital Corporation
Jerry E. Toepfer, Director, Co-Founder
Owner and President of Imageworx, a partner of Labelworx, and a partner of Greenmarket Purveying Company. Specializing in cosmetic, medical, and pharmaceutical packaging, and experienced in sales management, business development, and growth management in a manufacturing setting
Matthew E. Silpe, Director, Co-Founder
Experienced business executive and entrepreneur. Currently the Chief Operating Officer of June Jacobs Labs (JJL), an industry leader in the development and manufacturing of personal care products, and Principal of Millennium Capital Group, a company he founded
Theodore E. Staahl, M.D., Director
Cosmetic and Reconstructive Surgeon and founder at the Center for Cosmetic Surgery; Past-President of the California Academy of Cosmetic Surgeons

Scientific Advisory Board

Juan Carlos Alvarez, MAIS, RCP, AE-C, CCE, CTI
Senior Clinical Coordinator, Genentech/Roche Pharmaceuticals. Idiopathic Pulmonary Fibrosis Clinical Educator for patients and medical professionals

Teresa Barnes
Led all advocacy efforts for the Coalition for Pulmonary Fibrosis (CPF), and also created Fibrosis Across Organs effort (convened by the American Thoracic Society – ATS)

Rick Cantwell
SME on counterterrorist procedures and methodologies. Chairman of the Homeland Security Task Force. Co-chairs the Charlotte-Mecklenburg Homeland Security Working Group

Getaw Hassen, M.D., Ph.D. 

Emergency Medicine Faculty at Columbia University and H&H – Metropolitan Hospital, where he leads the research and 3D-printer medical simulation divisions for the Department. He is the author of over 94 academic publications

Jacob Finkelstein, Ph.D.
Professor in the Departments of Pediatrics, Neonatology and Environmental Medicine at the University of Rochester Medical Center

Subhrajit Saha, Ph.D.
Assistant Professor in Department of Radiation Oncology at Kansas University Medical Center. Member of KU Cancer Center, has a secondary appointment in Department of Cancer Biology

Susan Leeman, Ph.D.
Professor in the Department of Pharmacology and Experimental Therapeutics at the Boston University School of Medicine

Bert Maidment, Ph.D.
Former Associate Director of the Radiation and Nuclear Countermeasures Program (RNCP) at the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Allergy, Immunology and Transplantation

Ron Manning, Ph.D.
Former Branch Chief, Chemical, Radiological and Nuclear Medical Countermeasures; Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures; Biomedical Advanced Research and Development Authority (BARDA)

Albert Polito, M.D.
Chief of the Division of Pulmonary Medicine of Mercy Medical Center, Directed the Pulmonary Outpatient Clinics and the Pulmonary Fellowship Program at John’s Hopkins Medical School

Pranela Rameshwar, Ph.D.
Professor at the Rutgers New Jersey Medical School, Department of Medicine, Division of Hematology-Oncology

Ted Ross, Ph.D.
Director, Center for Vaccines and Immunology and Professor, GRA Eminent Scholar of Infectious Disease, University of Georgia College of Veterinary Medicine

 

Covid Hot Spots